Botox approval
This article was originally published in The Rose Sheet
Executive Summary
Allergan will market prescription drug Botox Cosmetic with $40 mil.-$50 mil. ad campaign following FDA approval April 15, Irvine, Calif. company says. Botulinum Toxin Type A, already widely used in cosmetic surgery, was formally approved by the agency for cosmetic use to "to temporarily improve the appearance of moderate to severe frown lines between the eyebrows," FDA announces. When injected into skin in small doses, the toxin paralyzes or weakens the muscle, FDA says, noting the majority of investigators and 405 patients evaluated in placebo-controlled, multi-center randomized clinical trials noticed an improvement in lines when injected with Botox. More than 850,000 people had Botox injections in 2001, according to American Society of Plastic Surgeons...